DK178709B1 - Anvendelse af zinc- og kobbergluconater i behandlingen af digital dermatitis - Google Patents
Anvendelse af zinc- og kobbergluconater i behandlingen af digital dermatitis Download PDFInfo
- Publication number
- DK178709B1 DK178709B1 DKPA201500345A DKPA201500345A DK178709B1 DK 178709 B1 DK178709 B1 DK 178709B1 DK PA201500345 A DKPA201500345 A DK PA201500345A DK PA201500345 A DKPA201500345 A DK PA201500345A DK 178709 B1 DK178709 B1 DK 178709B1
- Authority
- DK
- Denmark
- Prior art keywords
- gluconate
- zinc
- copper
- treatment
- digital dermatitis
- Prior art date
Links
- 208000006413 Digital Dermatitis Diseases 0.000 title claims abstract description 118
- 238000011282 treatment Methods 0.000 title claims abstract description 94
- 208000023867 digital dermatitis in cattle Diseases 0.000 title claims abstract description 92
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 title claims abstract description 84
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 239000011701 zinc Substances 0.000 title claims abstract description 71
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 70
- 229940108925 copper gluconate Drugs 0.000 claims abstract description 80
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 78
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 78
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 78
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 78
- 241001465754 Metazoa Species 0.000 claims abstract description 67
- 244000144980 herd Species 0.000 claims abstract description 59
- 241000283690 Bos taurus Species 0.000 claims abstract description 56
- 230000003902 lesion Effects 0.000 claims abstract description 55
- 239000010949 copper Substances 0.000 claims abstract description 47
- 229910052802 copper Inorganic materials 0.000 claims abstract description 47
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 46
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 44
- 230000000699 topical effect Effects 0.000 claims abstract description 23
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000037213 diet Effects 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 239000003674 animal food additive Substances 0.000 claims 5
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000237852 Mollusca Species 0.000 claims 1
- 238000011970 concomitant therapy Methods 0.000 claims 1
- 244000062645 predators Species 0.000 claims 1
- 210000000078 claw Anatomy 0.000 abstract description 52
- 238000000034 method Methods 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 27
- 239000008267 milk Substances 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 235000013365 dairy product Nutrition 0.000 description 10
- 235000013373 food additive Nutrition 0.000 description 10
- 239000002778 food additive Substances 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 235000010755 mineral Nutrition 0.000 description 10
- 239000011707 mineral Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 244000309465 heifer Species 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000009304 pastoral farming Methods 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 7
- -1 Zinc- and Copper Gluconates Chemical class 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000004460 silage Substances 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 241000306001 Cetartiodactyla Species 0.000 description 4
- 241000589886 Treponema Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229910000365 copper sulfate Inorganic materials 0.000 description 4
- 235000021472 generally recognized as safe Nutrition 0.000 description 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101100469268 Caenorhabditis elegans rpl-1 gene Proteins 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000015854 Heliotropium curassavicum Nutrition 0.000 description 1
- 244000301682 Heliotropium curassavicum Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 101100011077 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nnt-1 gene Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 101150069124 RAN1 gene Proteins 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910001779 copper mineral Inorganic materials 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910001656 zinc mineral Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (19)
- ANVENDELSE AF ZINC- OG KOBBERGLUCONATER I BEHANDLINGEN AF DIGITAL DERMATITIS1. Zinkgluconat til oral anvendelse i behandlingen af digital dermatitis hos et hovdyr.
- 2. Kobbergluconat til oral anvendelse i behandlingen af digital dermatitis hos et hovdyr.
- 3. Zinkgluconat og kobbergluconat til oral anvendelse i behandlingen af digital dermatitis hos et hovdyr.
- 4. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 1-3, hvor hovdyret er et tamhovdyr.
- 5. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 1-4, hvor tamhovdyret er kvæg, og den digitale dermatitis er digital dermatitis hos kvæg.
- 6. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 1-5, hvor zinkgluconatet og/eller kobbergluconatet er anvendt som et fodertilsætningsstof.
- 7. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 1-6, hvor zinkgluconatet og/eller kobbergluconatet er blandet med fuldfoder.
- 8. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 1-6, hvor zinkgluconatet og/eller kobbergluconatet er blandet til et koncentreret foder.
- 9. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 1-8, hvor zinkgluconatet og/eller kobbergluconatet anvendes samtidigt med en standard pleje med topisk behandling.
- 10. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge krav 9, hvor standardplejen med topisk behandling er en bandage med et antibakterielt middel og/eller et antisvampemiddel.
- 11. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge krav 10, hvor det antibakterielle middel er salicylsyre.
- 12. Zinkgluconat og/eller kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 1-11, hvor varigheden af behandlingen er mindst tre uger.
- 13. Kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 6-12, hvor mængden af kobber i fodertilsætningsstoffet er på mellem 5 og 40 mg kobber pr. kg tørfoder.
- 14. Kobbergluconat til oral anvendelse ifølge et hvilket som helst af kravene 6-13, hvor mængden af kobber i fodertilsætningsstoffet er på mellem 5 og 10 mg kobber pr. kg tørfoder.
- 15. Zinkgluconat til oral anvendelse ifølge et hvilket som helst af kravene 6-12, hvor mængden af zink i fodertilsætningsstoffet er på mellem 35 til 500 mg zink pr. kg tørfoder.
- 16. Zinkgluconat til oral anvendelse ifølge et hvilket som helst af kravene 6-10 og 15, hvor mængden af zink i fodertilsætningsstoffet er på mellem 40 til 60 mg zink pr. kg tørfoder.
- 17. Salicylsyrebandage til anvendelse i behandlingen af digital dermatitis hos et hovdyr samtidigt med zinkgluconat og kobbergluconat tilføjet til diæten til hovdyret.
- 18. Zinkgluconat og kobbergluconat til anvendelse i behandlingen og forebyggelse af digital dermatitis hos et hovdyr, i særdeleshed digital dermatitis hos kvæg, hvilken fremgangsmåde omfatter: tilsætning af zinkgluconat og kobbergluconat til dyrets foder i en mængde på mellem 35 til 500 mg zink pr. kg tørfoder og mellem 5 og 40 mg kobber pr. kg tørfoder i en periode på mindst 3 uger og samtidig behandling af en hvilken som helst diagnosticeret digital dermatitislæsion hos dyret med en standardpleje med topisk behandling, i særdeleshed med en salicylsyrebandage, indtil læsionen er helet.
- 19. Zinkgluconat og kobbergluconat til anvendelse i behandlingen og forebyggelse af digital dermatitis hos en besætning af hovdyr, i særdeleshed digital dermatitis hos en kvægbesætning, hvilken fremgangsmåde omfatter: tilsætning af zinkgluconat og kobbergluconat til besætningens foder i en mængde på mellem 35 til 500 mg zink pr. kg tørfoder pr. dyr og mellem 5 og 40 mg kobber pr. kg tørfoder pr. dyr og samtidig behandling med en standardpleje med topisk behandling, i særdeleshed med en topisk salicylsyrebandagebehandling af en hvilken som helst diagnosticeret digital dermatitislæsion hos dyrebesætningen, indtil læsionen er helet, forsat tilsætning af zinkgluconat og kobbergluconat til besætningen og samtidig behandling af en hvilken som helst diagnosticeret læsion i besætningen i mindst 3 måneder, fortrinsvis i mindst 6 måneder.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500345A DK178709B1 (da) | 2015-06-17 | 2015-06-17 | Anvendelse af zinc- og kobbergluconater i behandlingen af digital dermatitis |
| ES16811059T ES2949316T3 (es) | 2015-06-17 | 2016-06-17 | Uso oral de gluconatos de zinc y cobre en el tratamiento de la dermatitis digital |
| PCT/DK2016/050201 WO2016202346A1 (en) | 2015-06-17 | 2016-06-17 | Oral use of zinc- and copper gluconates in the treatment of digital dermatitis |
| US15/736,957 US10166212B2 (en) | 2015-06-17 | 2016-06-17 | Oral use of zinc and copper gluconates in the treatment of digital dermatitis |
| CA2989677A CA2989677C (en) | 2015-06-17 | 2016-06-17 | Oral use of zinc- and copper gluconates in the treatment of digital dermatitis |
| EP16811059.1A EP3310351B1 (en) | 2015-06-17 | 2016-06-17 | Oral use of zinc- and copper gluconates in the treatment of digital dermatitis |
| PL16811059.1T PL3310351T3 (pl) | 2015-06-17 | 2016-06-17 | Doustne zastosowanie glukonianów cynku i miedzi w leczeniu dermatitis digitalis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500345A DK178709B1 (da) | 2015-06-17 | 2015-06-17 | Anvendelse af zinc- og kobbergluconater i behandlingen af digital dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK201500345A1 DK201500345A1 (da) | 2016-11-28 |
| DK178709B1 true DK178709B1 (da) | 2016-11-28 |
Family
ID=57357101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA201500345A DK178709B1 (da) | 2015-06-17 | 2015-06-17 | Anvendelse af zinc- og kobbergluconater i behandlingen af digital dermatitis |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10166212B2 (da) |
| EP (1) | EP3310351B1 (da) |
| CA (1) | CA2989677C (da) |
| DK (1) | DK178709B1 (da) |
| ES (1) | ES2949316T3 (da) |
| PL (1) | PL3310351T3 (da) |
| WO (1) | WO2016202346A1 (da) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4214996A (en) * | 1978-12-19 | 1980-07-29 | R.G.B. Laboratories, Inc. | Mineral enrichment composition and method of preparing same |
| US5780064A (en) * | 1997-09-12 | 1998-07-14 | Babson Bros. Co. | Germicidal compositions for the treatment of animal infectious diseases of the hoof |
| EP1787637A2 (en) * | 2005-08-18 | 2007-05-23 | Francisco Caballero Gobern | Composition for veterinary use |
| WO2011051295A1 (en) * | 2009-10-30 | 2011-05-05 | Akzo Nobel Chemicals International B.V. | Use of a metal supplement in animal feed |
| US20140179645A1 (en) * | 2012-12-21 | 2014-06-26 | The Pisces Group Llc | Antimicrobial compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5151274A (en) * | 1990-08-06 | 1992-09-29 | The Procter & Gamble Company | Calcium and trace mineral supplements |
| WO1993020749A1 (en) * | 1992-04-16 | 1993-10-28 | Gevins Alan S | Eeg spatial enhancement method and system |
| NL1004488C2 (nl) * | 1996-11-11 | 1998-05-14 | Minotara Corp N V | Waterig voedingsmiddel hoofdzakelijk op basis van een zuur en/of derivaten hiervan. |
| CA2386423C (en) * | 1999-10-04 | 2009-07-21 | John Carter | Pharmaceutical compositions containing copper, salicylic acid and vitamines c |
| US20100233291A1 (en) * | 2009-03-12 | 2010-09-16 | Dennis Smithyman | Animal lesion treatment and prevention formulations and methods |
| NL2009707C2 (en) | 2012-10-26 | 2013-06-13 | Intracare B V | Treatment and prevention of epithelial infections. |
| BR112015019387A2 (pt) * | 2013-02-15 | 2017-07-18 | Wellmark Int | alimentação mineral - através de formulação |
-
2015
- 2015-06-17 DK DKPA201500345A patent/DK178709B1/da active
-
2016
- 2016-06-17 WO PCT/DK2016/050201 patent/WO2016202346A1/en not_active Ceased
- 2016-06-17 EP EP16811059.1A patent/EP3310351B1/en active Active
- 2016-06-17 ES ES16811059T patent/ES2949316T3/es active Active
- 2016-06-17 US US15/736,957 patent/US10166212B2/en active Active
- 2016-06-17 PL PL16811059.1T patent/PL3310351T3/pl unknown
- 2016-06-17 CA CA2989677A patent/CA2989677C/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4214996A (en) * | 1978-12-19 | 1980-07-29 | R.G.B. Laboratories, Inc. | Mineral enrichment composition and method of preparing same |
| US5780064A (en) * | 1997-09-12 | 1998-07-14 | Babson Bros. Co. | Germicidal compositions for the treatment of animal infectious diseases of the hoof |
| EP1787637A2 (en) * | 2005-08-18 | 2007-05-23 | Francisco Caballero Gobern | Composition for veterinary use |
| WO2011051295A1 (en) * | 2009-10-30 | 2011-05-05 | Akzo Nobel Chemicals International B.V. | Use of a metal supplement in animal feed |
| US20140179645A1 (en) * | 2012-12-21 | 2014-06-26 | The Pisces Group Llc | Antimicrobial compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3310351A1 (en) | 2018-04-25 |
| EP3310351C0 (en) | 2023-06-07 |
| EP3310351B1 (en) | 2023-06-07 |
| PL3310351T3 (pl) | 2023-10-30 |
| ES2949316T3 (es) | 2023-09-27 |
| CA2989677A1 (en) | 2016-12-22 |
| WO2016202346A1 (en) | 2016-12-22 |
| CA2989677C (en) | 2023-08-22 |
| US20180169056A1 (en) | 2018-06-21 |
| DK201500345A1 (da) | 2016-11-28 |
| US10166212B2 (en) | 2019-01-01 |
| EP3310351A4 (en) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60212964T2 (de) | Zusammensetzungen zur behandlung von tierischen krankheiten und syndromen mit transferfaktor | |
| Holzhauer et al. | Clinical course of digital dermatitis lesions in an endemically infected herd without preventive herd strategies | |
| JP2023503437A (ja) | 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用 | |
| EA017656B1 (ru) | Композиция для профилактики и лечения дизентерии свиней | |
| Weber et al. | Comparison of the therapeutic efficacy of salicylic acid paste with a polyurethane wound dressing for the treatment of digital dermatitis lesions in dairy cows | |
| CN119278033A (zh) | 减少泌乳和改善健康的化合物 | |
| EP3310351B1 (en) | Oral use of zinc- and copper gluconates in the treatment of digital dermatitis | |
| Guard | Control programs for digital dermatitis | |
| Manzoor et al. | Production diseases and its management in dairy animals | |
| Seymour et al. | Evaluating lactation performance of multiparous dairy cattle to prepartum and/or postpartum supplementation of fat-embedded calcium gluconate | |
| Cireșan et al. | The importance of bovine foot bathing in the control and prevention of claw diseases. | |
| Mushtaq et al. | Effect of prepartum levamisole therapy on postpartum udder health in dairy cows. | |
| Holzhauer | Digital Dermatitis in Dairy Cattle Is Still a Serious Problem in Western Europe | |
| RU2786919C1 (ru) | Способ лечения болезней бактериальной этиологии у животных | |
| Yadav et al. | Medical management of Dipylidium caninum infected female cat: A case report | |
| Astiz et al. | Efficacy of long-acting moxidectin against sarcoptic mange in naturally infested sheep. | |
| Shaikh et al. | Geriatric diseases of goats | |
| Dotinga | The cure rate of individual chlortetracycline spray treatment on digital dermatitis in dairy cattle | |
| Beteg et al. | Observations concerning the use a biodegradable propolis extract, for metaphylaxis and treatment of podal diseases in dairy cows-preliminary study. | |
| RU2404728C1 (ru) | Способ повышения общей резистентности организма, профилактики и лечения респираторных, желудочно-кишечных и гинекологических заболеваний, профилактики эмбриональной смертности у животных и лекарственное средство для его осуществления | |
| CN113244220A (zh) | 穿琥宁在制备治疗奶牛乳房炎的兽用药物中的应用及穿琥宁兽用药剂 | |
| RU2706124C1 (ru) | Способ лечения субклинического мастита коров | |
| Bergsten | Laminitis: causes, risk factors, and prevention | |
| Gimranov et al. | Hematology of dairy cows with purulent-necrotic processes in the digital area treated with Subtilin ointment | |
| Mukherjee et al. | Mammary Gland Disorders |